GlassScriptPhysician profile
Danielle K Malchow
NPI 1629450051
$3,821.55
in general payments reported to CMS, 2019-2025
30 companies · $843 in 2025
The $843 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $623 · 2022: $671 · 2023: $796 · 2024: $889 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,527.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,677.53 | 2021-2025 | |
| Novo Nordisk INC | $279.92 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $277.89 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $240.11 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $227.59 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.57 | 2025 | Caplyta |
| Exact Sciences Corporation | $92.20 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $75.92 | 2022-2024 | Invega Sustenna, Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $75.71 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.54 | 2021-2024 | |
| Amgen INC. | $66.70 | 2021-2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $61.19 | 2022-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.13 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $59.52 | 2023-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $52.28 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $45.51 | 2021-2025 | Austedo Xr, Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.26 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $37.56 | 2021 | |
| Abiomed | $34.71 | 2025 | |
| Astellas Pharma US INC | $33.50 | 2023 | Myrbetriq, Veozah |
| Phathom Pharmaceuticals, INC. | $26.71 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $25.52 | 2021 | |
| Gilead Sciences, INC. | $23.74 | 2025 | Epclusa |
| Idorsia Pharmaceuticals US INC | $14.18 | 2023 | Quviviq |
| Lexicon Pharmaceuticals, INC. | $13.68 | 2023 | Inpefa |
| Novartis Pharmaceuticals Corporation | $13.58 | 2022 | |
| Organon LLC | $13.23 | 2023 | Nexplanon |
| Vanda Pharmaceuticals INC. | $13.18 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.98 | 2022 | |
| Dexcom, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Malchow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.